Safety and Efficacy of Asundexian in Cardiovascular Diseases, Updated Systemic Review and Meta Analysis.
BackgroundThromboembolic events remain a major cause of morbidity and mortality in cardiovascular diseases. Asundexian, an oral factor XIa inhibitor, has been proposed to reduce thrombosis while minimizing bleeding risk. The recent OCEANIC-STROKE trial provided substantial new evidence. We conducted an updated systemat...